Nanfang Hospital Hematology: Leukemia Assessment and Specialist Teams

Nanfang Hospital hematology in context

Nanfang Hospital is the affiliated hospital of Southern Medical University in Guangzhou, and its hematology department is listed among national clinical key specialties. In the 2023 Fudan national specialty reputation list, Nanfang hematology held position 7. That is a dated historical reference to a department-level reputation list, not a current ranking, a ranking of subspecialties or an assessment of any individual clinician.

For an overseas patient, the practical point is narrower than a ranking. What matters is whether the department's documented directions match the case in front of you, and which clinician would actually review the records. A reputation list cannot answer either question. The treating team decides suitability after seeing the case, and an enquiry does not establish acceptance.

Documented disease directions and how they differ

The department's documented directions include acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoma and myeloma, myeloproliferative neoplasms, red-cell disorders and bleeding diseases. These are distinct clinical problems, and the questions a patient brings differ accordingly. Someone with a new acute leukemia question may want to know how the diagnosis was established and what the existing marrow and genetic reports already show. Someone with lymphoma or myeloma may be asking for a review of a tissue diagnosis and prior treatment history. A person with a myeloproliferative neoplasm may be weighing longer-term monitoring against a change of plan. A bleeding disorder raises different questions again, often about pattern over time and laboratory confirmation. Naming the direction you are in helps the receiving team route the enquiry to the right reviewer.

A September 2025 hospital-authored profile describes attention to genetic differences and clinical response in leukemia assessment, and notes subspecialty collaboration since 2015 with physician rotations and case and research discussions. For a patient, that suggests a review may draw on more than one clinical perspective, but it does not mean every case receives the same process. Ask the receiving clinician which findings they need and how a records-based opinion would be structured.

The department has also documented a rare-blood-disease academic direction. A July 2021 hospital report described a provincial pharmacy society rare-blood-disease group and a South China coagulation forum held in Zhuhai on 10 July 2021, where hemophilia, basic-to-clinical research and multidisciplinary clinical and pharmacy cooperation were discussed. That was an academic meeting, not a clinical trial, and it does not establish any treatment, drug or access claim.

Named people and their documented roles

Liu Qifa is identified in a 19 March 2025 Southern Medical University profile as the hematology academic leader and a tenured professor. A 10 September 2025 hospital-authored profile additionally identifies him as director of the Southern Medical University hematology research institute. These are the roles the sources support; they are not a statement about outpatient availability or a bookable clinic.

Xuan Li was identified in an 8 October 2023 profile as hematology deputy director, professor and associate chief physician, with basic and clinical research in malignant blood diseases. That dated title should be read as a 2023 record, not assumed to be a current 2026 post. For a patient, the useful follow-up is to ask who currently holds the relevant clinical role and whether that person takes part in the assessment route being considered. A dated profile tells you the direction of someone's documented work; it does not confirm today's clinic list.

Sun Jing, a Nanfang hematology professor, was appointed leader of the rare-blood-disease group at its July 2021 founding, and Zhang Qing, pharmacy director, was appointed deputy leader. Those are dated academic society roles, not department-chief appointments or current clinic listings.

For a patient, the useful question is not simply who is senior. It is which clinician's documented interest matches the case, and whether that person is involved in the assessment route the hospital offers. A research institute directorship or a society role does not by itself confirm that the same person will see an individual patient.

Research infrastructure and what it can and cannot tell you

The 19 March 2025 profile states that the department established a clinical biobank and cohort and organized longitudinal follow-up starting in 2015, including samples collected before, during and after care. This is observational research infrastructure. It supports the study of how patients are assessed and followed over time; it is not a randomized trial and does not by itself prove that any treatment works better.

That distinction matters when reading about a department's research. A cohort with longitudinal samples can help clinicians and researchers examine patterns and generate questions. It does not answer an individual patient's question about which treatment is suitable. A reasonable question for the receiving team is whether your own earlier results can be read alongside later ones, and what the team would need in order to do that. Ask how conclusions from a records review are documented, and which parts would need an in-person visit. Those questions keep the conversation on your case rather than on the department's research output.

An overseas patient can reasonably ask whether the assessment will include a review of prior genetic and laboratory findings, and how the team documents its conclusions. Those questions are about the clinical process, not about access to research. Participation in any study would require separate eligibility review and consent, and this feature makes no claim that any study is open or available.

Department and individual honors, correctly attributed

Honors are most useful as a map of where a department has been recognized, not as a prediction about your case. When preparing questions, separate what belongs to the department, what belongs to a named person and what belongs to a project. Then ask which of those distinctions actually bears on the assessment you are seeking. A team award says nothing about an individual clinician's current availability, and a personal award says nothing about outcomes for any patient.

Individual honors are attributed to the named person. Liu Qifa's March 2025 profile documents recognition as a national outstanding physician, the Ding Ying award and a State Council allowance; the source does not supply award years, so none are stated here. Xuan Li's October 2023 profile records the Guangzhou Pearl River rising science talent award in 2018, the Yangcheng young good doctor recognition in 2019 and a Guangdong special-support young innovation talent award in 2022. These are personal recognitions, not evidence of outcomes for any patient.

It is worth asking, plainly, who will be responsible for reviewing your records and whether that person's documented interest matches your question. Academic recognition can indicate a field of work; it does not tell you who will be in the room, or on the call, for your consultation. Put that question to the receiving team rather than inferring it from an award list.

Practical decisions before seeking a leukemia assessment

Start with the clinical question you need answered. Is it confirmation of the diagnosis, a review of prior treatment, or a second opinion on the next stage? Then ask the receiving team which of your existing records are relevant before sending anything or arranging new tests. A pathology or marrow report, genetic and laboratory results, imaging summaries and a treatment chronology may all matter, but the team should tell you what it needs for this particular question.

Ask specifically how the assessment handles genetic differences and clinical response, and who will review the records. Ask what the team can and cannot conclude from a records-based review, and what would require an in-person visit. The treating team decides suitability and scheduling; an enquiry does not establish acceptance.

How ChinaSpecialistCare can help

ChinaSpecialistCare can coordinate an independent specialist appointment or records-based review for a leukemia assessment at a suitable Chinese hospital, including help organizing records and preparing questions. We do not represent Nanfang Hospital, and hospital acceptance, clinical decisions and fees remain with the treating team. An initial enquiry is free.

Blood disorder and blood cancer care